Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS – Get Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 193,285 shares, an increase of 513.6% from the May 31st total of 31,498 shares. Based on an average daily volume of 12,405,724 shares, the days-to-cover ratio is currently 0.0 days. Currently, 4.6% of the shares of the company are short sold.
Cyclacel Pharmaceuticals Stock Down 0.2%
NASDAQ:BGMS traded down $0.00 during midday trading on Friday, reaching $0.60. The stock had a trading volume of 38,690 shares, compared to its average volume of 7,035,767. The firm has a fifty day simple moving average of $0.95 and a two-hundred day simple moving average of $1.10. Cyclacel Pharmaceuticals has a 12-month low of $0.57 and a 12-month high of $19.87. The stock has a market cap of $3.32 million, a P/E ratio of -0.13 and a beta of -0.40.
Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.04) EPS for the quarter.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.
Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.
Recommended Stories
- Five stocks we like better than Cyclacel Pharmaceuticals
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
- Capri’s Turnaround Is Taking Shape, But Is the Stock a Buy Yet?
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
